Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other Non-Current Liabilities (2016 - 2021)

Spero Therapeutics (SPRO) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $100000.0 as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Other Non-Current Liabilities changed N/A year-over-year to $100000.0, compared with a TTM value of $100000.0 through Sep 2022, changed N/A, and an annual FY2021 reading of $802000.0, changed N/A over the prior year.
  • Other Non-Current Liabilities was $100000.0 for Q3 2022 at Spero Therapeutics, roughly flat from $100000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $1.0 million in Q1 2022 and bottomed at $100000.0 in Q2 2022.
  • Average Other Non-Current Liabilities over 5 years is $324800.0, with a median of $200000.0 recorded in 2019.
  • The sharpest move saw Other Non-Current Liabilities rose 11.5% in 2018, then decreased 10.31% in 2019.
  • Year by year, Other Non-Current Liabilities stood at $223000.0 in 2018, then decreased by 10.31% to $200000.0 in 2019, then changed by 0.0% to $200000.0 in 2020, then surged by 301.0% to $802000.0 in 2021, then tumbled by 87.53% to $100000.0 in 2022.
  • Business Quant data shows Other Non-Current Liabilities for SPRO at $100000.0 in Q3 2022, $100000.0 in Q2 2022, and $1.0 million in Q1 2022.